Sign in to view content

Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema

John W. Kitchens, MD

Video
Published 2022

Related

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021
Association Between Early Vision-Related Quality of Life (QoL) Outcomes and Anatomic Dryness in neovascular AMD and DME in the VIEW and FAME trials
Michael A. Singer, MD
On Demand Cases, Courses, and Papers
2019
Outcomes of Eyes Lost to Follow-up After Treatment With Intraocular and Periocular Steroid Injections
John W Hinkle, MD
On Demand Cases, Courses, and Papers
2021

Category: Diabetic Retinopathy

See more